Objective-To devise assays to assess and follow the specific antibody response in patients treated with streptokinase for acute myocardial infarction.
Abstract
Objective-To devise assays to assess and follow the specific antibody response in patients treated with streptokinase for acute myocardial infarction.
Design-Venous blood samples were collected before treatment with streptokinase started and subsequently at regular intervals over one year. Specific IgG and subclass IgGi were assessed by an enzyme linked immunosorbent assay.
Setting-Coronary care unit in a general hospital.
Patients-48 patients with acute myocardial infarction: 22 patients had venous blood samples taken at presentation only; serial blood samples were taken from 20 patients who then received thrombolytic therapy with streptokinase and six patients who were unsuitable for thrombolytic therapy.
Results-Titres of antibodies to streptokinase were low at presentation in 36 (75%) of the 48 patients. Serial measurements made in 20 patients showed the virtual disappearance of antibody within the first 24 hours. This was followed by a steady increase in the specific IgGl titre, which peaked at day 14 before gradually declining. Values at one year remained significantly higher than baseline values. There was no evidence of an IgM response in the patients studied.
Conclusion-Low titres of antibodies to streptokinase were IgGI. The optical density value corresponding to the standard fixed dilution was obtained and the corresponding dilution giving the same optical density was derived from the dilution curve for each patient sample. The value obtained in this way from the patient dilution curve was taken as the result for that patient's serum. The reciprocal of the dilution was taken as the antibody titre (fig 2) . Where undiluted patient serum did not achieve the optical density of the fixed standard plasma dilution the result was taken as zero for statistical purposes.
The validity of the assay was confirmed by pre-incubating pure streptokinase with positive serum in a separate experiment. When the sample was tested subsequently with the ELISAs a negative result was obtained.
The reproducibility of the assays was determined at the upper and lower ranges. For the low antibody titres we tested a patient's sample obtained before treatment. We tested within batch reproducibility by measuring the same sample six times on the same plate. At a mean IgG titre of 19 the within batch coefficient of variation (CV) was 14-7%. It was 12-7% for IgGl (mean titre = 12). Between batch reproducibility was assessed by assaying the same sample six times on different days. The between batch CV was 29% for IgG and 31-8% for IgGl.
For the high titres the reproducibility was assessed by using a patient's sample obtained 14 days after streptokinase treatment. At a mean IgG titre of 4200 the within batch CV was 6-9% and the between batch CV was 12-9%. Results for IgGI (mean titre = 1750) gave a within batch CV of 7-7% and between batch CV of 14-2%.
Total plasma IgG and IgM were assessed by single radial immunodiffusion11 12 on prepoured plates (Binding Site, University of Birmingham) at presentation in the 20 patients followed after streptokinase therapy and the six patients who were not treated with streptokinase. All results are expressed as mean (SE). The statistical significance of differences between patient groups and between daily data was determined by the Wilcoxon rank sum test for paired and unpaired data.
All patients gave informed consent and the study was approved by the local ethics committee.
Results
Twelve of the 48 patients had no detectable IgG anti-streptokinase antibody before treatment. The remaining 36 patients had titres varying from 1 to 140. Figure 3 Reciprocal of antibody titre undetectable in 17 of the patients (mean titre 3 (2)). Subsequently there was a gradual increase and by day 4 the titre (91 (41)) was significantly higher than baseline concentrations (p = 0-0 18). The titre increased further by day 7 reaching a peak on day 14 (mean titre 3192 (771) (p < 0 0001)). Subsequently, the titre gradually declined, levelling off after about six months. However, by one year the mean titre (131 (36)) was still higher than the baseline value (p < 0-025).
The pattern of IgGl results resembled that for IgG. IgGl titres were detectable in 13 patients (mean 26 (7)). Within 24 hours of treatment with streptokinase the titre decreased to 1 (1-47) (p = 0 003). Subsequently it rose and it was significantly increased by day 4 (mean 79 (27) (p = 0-02)). It reached a peak on day 14 (mean 1751 (589) (p = 0 0004)) and declined to 107 (41) (p < 0-025) by one year. Figure 5 summarises the results.
There was no evidence of IgG2, IgG3, or IgG4 antibodies to streptokinase and only low titres of IgM (< 1/30) which did not alter over the period of the study.
There was a large variation in the antibody response. Though the baseline titres were relatively similar for all patients, peak titres for IgG varied from 140 to 10 000, and two patients had peak titres of <200. However, even these patients showed no IgM antibody response to streptokinase even though total IgM and IgG were normal.
The six control patients who did not receive streptokinase had a mean baseline IgG titre of 10 (5) which was similar to that of the patients who received the drug. This titre did not change in the 28 days after the infarct (day 1 = 14 (7); day 4 = 11 (6) The time course of the secondary immune response seen here resembles that described by Jalihal et al "for streptokinase neutralising capacity",'4 indicating that the neutralisation is probably due to antibody. Jalihal et al suggested that the streptokinase dose should be titrated to overcome this neutralising capacity in patients in whom it is high. Our study suggests that if antibody is responsible for neutralisation, the dose would need to be increased if a patient presented with a second myocardial infarction within one year of the initial treatment. The administration of an increased dose of streptokinase within this period could lead to an immune reaction as well as a failure to achieve an adequate thrombolytic state. However, this possibility remains theoretical at present and further studies will be required to clarify the role and implications of these antibodies. Nevertheless, until their role has been clarified, it would be prudent to avoid repeating the dose between three days and at least one year after the initial therapy. During this period an alternative nonstreptokinase thrombolytic agent could be used.
